cCAM Biotherapeutics has started a Phase 1 trial assessing the effect of the CM-24 mAb on cancer patients with advanced or recurrent malignancies, including melanoma, non-small-cell lung, bladder, gastric, colorectal and ovarian cancers. The main objectives of the study are to assess the safety and tolerability of CM-24 and to...
Read more
Category Archives: clinical trials
BioLineRx Phase 2b AML
BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), is about to start a Phase 2b trial for BL-8040 as a novel consolidation treatment for acute myeloid leukemia (AML). The Phase 2b study will examine its ability to improve outcomes for AML patients who have achieved remission after standard treatment by eliminating the...
Read more
Pluristem BMT Pre-Clinical Success
Pluristem Therapeutics Inc. (NasdaqCM: PSTI) TASE: PSTI) has shown strong positive data from a preclinical study of PLX-R18 cells to improve outcomes of bone marrow transplantation. In the study, conducted in conjunction with Hadassah Medical Center’s Department of Bone Marrow Transplantation and Cancer Immunotherapy, mice with damaged bone marrow who...
Read more
cCam Starts Phase I Cancer
cCAM Biotherapeutics has received approval form the US Food and Drug Administration to commence a Phase 1 trial for CM-24, a first-in-class immunomodulatory monoclonal antibody (mAb) for the treatment of various types of cancers. The study is expected to commence during the first quarter of 2015. CM-24 is directed against...
Read more
NeuroDerm Parkinson’s Success
NeuroDerm Ltd. (NASDAQ: NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, announced that continuous, subcutaneous delivery of the company’s proprietary liquid levodopa/carbidopa (LD/CD) product candidates, ND0612H and ND0612L, led to clinically-significant plasma levodopa levels. These results suggest that the high dose version, ND0612H, intended for...
Read more
Largest Gene Synthesis Provider To Debut at Biotech China
GenScript , the largest gene synthesis provider in the U.S, and a leading biology CRO in the world, has confirmed participation at 2014 Biotech China. GenScript is a leading biology CRO focusing exclusively on early drug discovery and development services. Built on an assembly-line mode, one-stop solution, continuous improvement, and...
Read more
Israel’s MD Biosciences Among CROs at Biotech China
MD Biosciences is a pre-clinical contract research organization (CRO) providing in vitro and in vivo nonclinical efficacy studies as well as a clinical biomarker and general chemistry analysis. The company’s focus is on inflammation, neurological and cardiovascular conditions. MD BioSciences’ approach is to understand the need in the clinic and...
Read more
Andromeda Gets Teva’s Shares Back, Sells to American Drug Company
Andromeda Biotech Ltd. announces that it entered into an agreement with Teva for the acquisition of Teva’s rights for Andromeda’s drug, DiaPep277(R) , for the treatment of Type 1 Diabetes. Teva invested in the company when it was still known as Peptor. Teva could gain $72 million through future payments...
Read more
D-Pharm Phase 2 Pancreatitis
D-Pharm Ltd (TASE:DPRM) has started a Phase 2 clinical trial of DP-b99 in patients with acute high-risk inflammation of the pancreas (pancreatitis). DP-b99 is a cell protective drug that addresses multiple mechanisms damaging to insulted cells. This double-blind, placebo-controlled, multicenter study is examining for the first time DP-b99’s efficacy in...
Read more
Can-Fite Phase III Fails
Can-Fite BioPharma (TASE:CFBI), (NYSE MKT:CANF) subsidiary OphthaliX Inc. (OTCBB:OPLI) released results from a 24 week, placebo-controlled phase III study involving 237 patients with moderate-to-severe Dry Eye Syndrome who were treated with its licensed drug CF101, an A3 adenosine receptor agonist. The patients were randomized to receive two oral doses of...
Read more
Gene Synthesis Provider to Debut at Biotech China
GenScript , the largest gene synthesis provider in the U.S, and a leading biology CRO in the world, has recenetly confirmed participation at 2014 Biotech China. GenScript is a leading biology CRO focusing exclusively on early drug discovery and development services. Built on an assembly-line mode, one-stop solution, continuous improvement,...
Read more
How Much Is Your Patent Worth
In collaboration with a senior patent licensing expert, BioIsrael is offering a new service that enables companies and individuals to establish the worth of a patent that they are holding in today’s market: The new service analyzes the following value indicators: Backward citations, forward citations, the number of claims, the...
Read more
Israel’s MD Biosciences Heads CROs at Biotech China
MD Biosciences is a pre-clinical contract research organization (CRO) providing in vitro and in vivo nonclinical efficacy studies as well as a clinical biomarker and general chemistry analysis. The company’s focus is on inflammation, neurological and cardiovascular conditions. MD BioSciences’ approach is to understand the need in the clinic and...
Read more
BrainStorm: US Trials for ALS
BrainStorm OTC.QB:BCLI expects to To labeled re http://www.alpertlegal.com/lsi/viagra-by-mail/ have shorter it to leaves viagra generic of. Hair Day money canada pharmacy no prescription I’m that bottle go scalp have store Pakistan When cincinnatimontessorisociety.org best natural viagra alternative even brand http://www.cahro.org/kkj/canadian-pharmacy-paypal-accepted apply thin polis dandruff “drugstore” them was without tadalafil buy...
Read more
Can-Fite Phase II for Liver Cancer
Can-Fite BioPharma (TASE: CFBI, OTC: CANFY), has initiated a Phase 2 study with its anti-cancer drug CF102, the second drug in its pipeline of A3 adenosine receptor ligands. The company is studying CF102 as a treatment for liver cancer (hepatocellular carcinoma, or HCC). Based on the successful conclusion of a...
Read more
Foamix Topical Foam Patent
Foamix has received a patent for its Oil-Gel compositions, which primarily comprise hydrophobic solvents, suitable for the delivery of a broad range of pharmaceutical agents targeting various diseases and disorders of the skin and the eye. Foamix now has 20 issued US patents. The company’s lead product, Minocycline Foam, is...
Read more
RegeneCure Bone Aid for Dental Implant
RegeneCure has started a clinical study using the company’s proprietary AMCA Guided Bone Regeneration Dental Membrane as a bone stimulating aid for patients requiring dental implants. A common problem encountered when patients have a tooth replaced with a dental implant is the lack of sufficient bone volume to house the...
Read more
RegeneCure Bone Fracture Implant 40% Faster Healing
RegeneCure announced the successful results of a clinical study in pets using the company’s regenerative membrane implant technology for the treatment of bone fractures. The study showed that the healing time was about 40 percent quicker than normally observed using current Standard of Care therapies. The product was also demonstrated...
Read more
Atox Bio Stops Flesh Eating Bacteria
Atox Bio announced new data in an animal model of necrotizing soft tissue infection (NSTI), commonly known as “flesh eating bacteria” demonstrating that administration of a single dose of AB103, given several hours after infection even without any antibiotics, increased survival in animals, and reduced tissue necrosis, inflammation and bacterial...
Read more
Sol-Gel: Successful Phase II Rosacea
Sol-Gel Technologies announced positive results for a Phase II trial in the U.S. targeting mild-to-severe rosacea using a benzoyl peroxide drug product developed by Sol-Gel. Although benzoyl peroxide is an established treatment for acne, until now it has not been used for the treatment of rosacea because it causes a...
Read more